These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21143152)

  • 21. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
    J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances.
    Wu H; Medeiros LJ; Young KH
    Blood Rev; 2018 Jan; 32(1):8-28. PubMed ID: 28802908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The challenges and perspectives in treating adolescent and young adult patients with hematological malignancies.
    Raanani P; Tallman MS
    Acta Haematol; 2014; 132(3-4):263. PubMed ID: 25228550
    [No Abstract]   [Full Text] [Related]  

  • 24. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.
    Bryan LJ; Gordon LI
    Blood Rev; 2015 Jan; 29(1):25-32. PubMed ID: 25260226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Editorial [hot topic: Therapeutic targeting of the sphingolipid "biostat" in hematologic malignancies (guest editors: Thomas P. Loughran and Hong-Gang Wang)].
    Loughran TP; Wang HG
    Anticancer Agents Med Chem; 2011 Nov; 11(9):780-1. PubMed ID: 22023044
    [No Abstract]   [Full Text] [Related]  

  • 26. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives.
    Hasselbalch HC; Larsen TS; Riley CH; Jensen MK; Kiladjian JJ
    Curr Drug Targets; 2011 Mar; 12(3):392-419. PubMed ID: 21143149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Notch Signaling: A Potential Therapeutic Target for Hematologic Malignancies.
    Gao L; Yuan K; Ding W; Lin M
    Crit Rev Eukaryot Gene Expr; 2016; 26(3):239-46. PubMed ID: 27650987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha interferon: new associations in haematology/oncology. The Montpellier experience.
    Rossi JF
    Med Oncol; 1995 Mar; 12(1):59-61. PubMed ID: 8542249
    [No Abstract]   [Full Text] [Related]  

  • 29. Amino acid metabolism in hematologic malignancies and the era of targeted therapy.
    Tabe Y; Lorenzi PL; Konopleva M
    Blood; 2019 Sep; 134(13):1014-1023. PubMed ID: 31416801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-1β as emerging therapeutic target in hematological malignancies and potentially in their complications.
    Arranz L; Arriero MDM; Villatoro A
    Blood Rev; 2017 Sep; 31(5):306-317. PubMed ID: 28495184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TNF-related apoptosis-inducing ligand (TRAIL) as the potential therapeutic target in hematological malignancies.
    Naimi A; Movassaghpour AA; Hagh MF; Talebi M; Entezari A; Jadidi-Niaragh F; Solali S
    Biomed Pharmacother; 2018 Feb; 98():566-576. PubMed ID: 29288972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies.
    Roberts AW; Stevenson FK
    Blood; 2021 Sep; 138(13):1089. PubMed ID: 34320159
    [No Abstract]   [Full Text] [Related]  

  • 33. An Empirical Study of the Prescription Pattern of Drugs for Hematological Malignancies in Japan from 2010-2014.
    Shibata S; Wayama Y; Tsuyuki A; Matsushita M; Chiba K; Matsuki E; Okamoto S; Suzuki T
    Biol Pharm Bull; 2017; 40(6):894-901. PubMed ID: 28566631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.
    Springuel L; Renauld JC; Knoops L
    Haematologica; 2015 Oct; 100(10):1240-53. PubMed ID: 26432382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hematologic Malignancies/Pediatric Malignancies New Therapeutic Strategy for Hematologic Malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2018 May; 45(5):793-794. PubMed ID: 30026439
    [No Abstract]   [Full Text] [Related]  

  • 36. Targeting the Na(+)/H(+) exchanger: an old concept with new perspectives in the treatment of hematological malignancies.
    Turturro F; Lawson M; Friday E; Welbourne T
    Leuk Res; 2007 Oct; 31(10):1449-50. PubMed ID: 17173969
    [No Abstract]   [Full Text] [Related]  

  • 37. Targeting Wnt signaling pseudokinases in hematological cancers.
    Karvonen H; Perttilä R; Niininen W; Barker H; Ungureanu D
    Eur J Haematol; 2018 Oct; 101(4):457-465. PubMed ID: 29989208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.
    Sankhala K; Giles FJ
    Expert Rev Hematol; 2009 Aug; 2(4):399-414. PubMed ID: 21082945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The importance of the telomere and telomerase system in hematological malignancies.
    Ram R; Uziel O; Lahav M
    Leuk Lymphoma; 2005 Aug; 46(8):1121-35. PubMed ID: 16085552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon-alpha therapy, protein kinase C-alpha and Langerhans cell histiocytosis.
    Brown RE
    Med Pediatr Oncol; 2003 Jul; 41(1):63-4. PubMed ID: 12764746
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.